- Home
- SOLV vs ROIV Comparison
SOLV vs ROIV Comparison
Compare SOLV & ROIV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SOLV
- ROIV
- Stock Information
- Founded
- SOLV 2023
- ROIV 2014
- Country
- SOLV United States
- ROIV United Kingdom
- Employees
- SOLV N/A
- ROIV N/A
- Industry
- SOLV
- ROIV Biotechnology: Pharmaceutical Preparations
- Sector
- SOLV
- ROIV Health Care
- Exchange
- SOLV NYSE
- ROIV Nasdaq
- Market Cap
- SOLV 12.7B
- ROIV 7.8B
- IPO Year
- SOLV N/A
- ROIV N/A
- Fundamental
- Price
- SOLV $73.75
- ROIV $11.40
- Analyst Decision
- SOLV Hold
- ROIV Buy
- Analyst Count
- SOLV 11
- ROIV 4
- Target Price
- SOLV $80.29
- ROIV $17.50
- AVG Volume (30 Days)
- SOLV 792.3K
- ROIV 7.9M
- Earning Date
- SOLV 08-07-2025
- ROIV 08-07-2025
- Dividend Yield
- SOLV N/A
- ROIV N/A
- EPS Growth
- SOLV N/A
- ROIV N/A
- EPS
- SOLV 2.18
- ROIV N/A
- Revenue
- SOLV $8,308,000,000.00
- ROIV $29,053,000.00
- Revenue This Year
- SOLV $4.11
- ROIV $3.28
- Revenue Next Year
- SOLV $0.14
- ROIV $156.84
- P/E Ratio
- SOLV $33.91
- ROIV N/A
- Revenue Growth
- SOLV 1.29
- ROIV N/A
- 52 Week Low
- SOLV $47.16
- ROIV $8.73
- 52 Week High
- SOLV $85.92
- ROIV $13.06
- Technical
- Relative Strength Index (RSI)
- SOLV N/A
- ROIV 54.55
- Support Level
- SOLV N/A
- ROIV $10.71
- Resistance Level
- SOLV N/A
- ROIV $11.58
- Average True Range (ATR)
- SOLV 0.00
- ROIV 0.29
- MACD
- SOLV 0.00
- ROIV 0.00
- Stochastic Oscillator
- SOLV 0.00
- ROIV 62.16
About SOLV SOLVENTUM CORP
Solventum Corp is a healthcare company developing, manufacturing, and commercializing a portfolio of solutions that leverage deep material science, data science, and digital capabilities to address critical customer and patient needs. The company has four operating segments: MedSurg, Dental Solutions, Health Information Systems, and Purification and Filtration. The company generates the majority of its revenue from the MedSurg segment, which provides wound care and surgical solutions that are intended to accelerate healing, prevent complications, and lower the total cost of care globally.
About ROIV Roivant Sciences Ltd.
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.